Help Center

The RNAscope in situ hybridization (ISH) technology provides a powerful method to detect gene expression within the spatial and morphological tissue context. The proprietary probe design, in combination with the advanced signal amplification enables highly specific and sensitive detection of target RNA with each dot representing a single RNA transcript. This robust signal-to-noise technology allows for the detection of gene transcripts at the single molecule level with single-cell resolution and can further expand our understanding of gene expression in cell lines and tissues samples. In this webinar, we will review various ACD product lines and discuss the utilization of each product line for specific applications.

• Introduction to the various product lines 
• Key applications that necessitate the use of the RNAscope, BaseScope™ and miRNAscope assays 

Visual detection and quantification of AAV and LV vector biodistribution and transgene expression in preclinical animal models with RNAscope™ and BaseScope™ in situ hybridization.

RNAscope in situ hybridization (ISH) has been described by its users as a means of “morphology-based AAV biodistribution analysis.” RNAscope in situ assays of AAV DNA and transgene mRNA combine the molecular sensitivity of qPCR with single-cell resolution and the context of tissue morphology. By combined RNAscope probes to AAV vector and transgene mRNA, vector copy number and expression can be visually assessed and quantified simultaneously in each cell of an intact fixed tissue. With the addition of cell marker probes in multiplex fluorescent RNAscope assays, AAV vector and transcript levels can be measured in any target cell type.
BaseScope ISH is another powerful tool facilitating gene therapy development.  Specific measurement of therapeutic human transgene expression in animal models is often impossible by IHC because of the high level of homology between transgene and animal ortholog transcripts.  BaseScope enables specific detection of even single nucleotide differences and can easily differentiate AAV human transgene from non-human primate and other animal ortholog sequences.
These assays are enabling more informative and efficient preclinical gene therapy development and contributing critical data in IND-enabling studies

Direct detection of viral RNA in human or other animal cells by RNA in situ hybridization (ISH) technology is a powerful tool to establish the etiology and pathogenesis of viral disease. Nucleic acid-based molecular detection methods have revolutionized viral detection, offering several essential advantages such as sensitivity, specificity, and speed. Beyond this, RNAscope ISH technology uniquely offers a molecular detection at a single cell resolution coupled with morphological context to enable visualization of the virus in different infected tissues and cell types. In this webinar, we will demonstrate how RNAscope technology can be used to detect viral infection and pathogenesis for research and enhance our understanding of globally important SARS-CoV2 virus.

• RNAscope Technology Overview
• Literature review showing how COVID-19 Detection and Probes deliver the results researchers seek
• Learn about the various COVID-19 Offerings (Bio-Techne) to further support your research findings in applications including viral detection, acquired immunity, vaccine efficacy and many more. 

Get a deeper understanding of gene expression patterns by using assays that retain spatial organization at single cell resolution! Come learn about the robust RNA in situ hybridization assay that enables the detection of ASOs, miRNAs, siRNAs, and other smaller RNAs (16-50nt) with spatial and morphological context at single cell resolution.

• Introduction to the miRNAscope technology and workflow 
• Key applications that necessitate the use of the miRNAscope Assay 
• Key benefits of the miRNAscope Assay for your research 

Using RNAscope ISH to detect cancer and immune markers in the tumor microenvironment at single-cell resolution

The study of the tumor microenvironment (TME) expands the understanding of cancer initiation, progression, and metastases. The RNAscope assay is an ideal solution to analyze specific cell types and states infiltrated in the TME within the morphological context. 

With RNAscope you can identify and characterize immune cell types, cytokines, chemokines, transcription factors, checkpoint markers, and more, all at the single cell level.

The RNAscope™ in situ hybridization (ISH) technology provides a powerful method to detect gene expression within the spatial and morphological tissue context. The proprietary “double Z” probe design in combination with the advanced signal amplification enables highly specific and sensitive detection of the target RNA with each dot visualizing a single RNA transcript. This robust signal-to-noise technology allows for the detection of gene transcripts at the single molecule level with single-cell resolution and can further expand our understanding of gene expression in cell lines and tissues samples.

The RNAscope™ technology provides pivotal single-cell information that is necessary to study novel cell populations in vital organs such as the liver and kidneys. Studying gene expression with spatial resolution can provide functional information for cellular sub-populations in turn improving our understanding of various disease pathologies.

• Understand complex spatial relationship among different cell types within the liver and kidneys.
• Identify and characterize novel cell types .
• Study expression of target genes implicated is liver and kidney diseases.

This webinar will provide an overview of how Bio-Techne’s Assay Services’ Team expertise in RNAscope technology is being utilized by Biopharma for the development of biomarkers and companion diagnostic assays to support their therapeutic programs. Advanced Cell Diagnostics’ RNAscope^TM in situ hybridization (ISH) platforms are widely utilized for high resolution tissue-based and cell-specific analysis of targets and biomarkers. The RNAscope ISH platform is clinically validated and enables quantitative expression analysis that has repeatedly been proven to better stratify treatment-responsive and non-responsive patients in therapeutic clinical trials compared to traditional methods such as IHC and qPCR. RNAscope is often more sensitive than IHC and provides cell-specific biomarker data in complex tissue microenvironments that qPCR cannot.

• Biomarker validation to accelerate translation of assays into clinical development in a GCLP setting in a matter of 4-6 weeks*
• Assay feasibility and development - sensitivity, specificity, and precision testing (repeatability & reproducibility)
• Development of pathologist scoring and HALO^TM image analysis algorithms for biomarker assessment.
• Established protocols for clinical assay transfer to CLIA-certified labs for prospective use.
• RNAscope multiplexing and validated protocols for co-detection of biomarkers and immune cell markers
• Quantifiable, cell-specific, single-molecule detection of RNA biomarkers in tumor biopsies
• Superior performance against traditional methods, e.g., IHC, qPCR
• Application in small molecule, biologic, and cell therapy biomarkers